Pain in primary care: an Italian survey

Koleva, Daniela; Krulichova, Iva; Bertolini, Guido; Caimi, Vittorio; Garattini, Livio

doi:10.1093/eurpub/cki033

Cited by 56 publications

(51 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These results do not differ significantly from other European practice studies [14][15][16]. Our practice study found the highest prevalence of chronic pain in the 70-79-year-old age group.…”

Section: Discussioncontrasting

confidence: 60%

See 1 more Smart Citation

Chronic Pain in German General Practice

et al. 2009

View full text Add to dashboard Cite

A B S T R A C TIntroduction. This study evaluates the prevalence of chronic pain, intensity of pain, activity limitation, and pain-related diagnoses in German general practices.Methods. In 40 general practices, up to 50 consecutive patients presenting to general practitioners (GP) for routine medical consultation were questioned, and those reporting pain that lasted for more than 3 months received a questionnaire referring to intensity of pain and activity limitations. GPs received a questionnaire asking about the duration of treatment and diagnoses.Results. Three hundred forty-six out of 1,860 questioned patients suffered from pain that lasted for more than 3 months (a point prevalence of 18.4% [95% confidence interval 16.7-20.3]). The average degree of pain equaled 5 out of 10 points on a numerical grading scale (NRS); the average degree of activity limitation was 4.8 out of 10. In most cases, the pain was related to musculoskeletal degenerative diseases. Conclusion.Chronic pain patients constitute a considerable share of workload in general practice.

show abstract

Section: Discussioncontrasting

confidence: 60%

“…Studies carried out in primary care settings in Finland [13], Sweden [14], Denmark [15], and Italy [16] showed point prevalence rates of 15-20%. Two small, nonrepresentative studies (one practice, respectively) were carried out in German general practice and demonstrated two different chronic pain ratios: 35% [17] and 20% [18].…”

Section: Introductionmentioning

confidence: 99%

Chronic Pain in German General Practice

et al. 2009

View full text Add to dashboard Cite

show abstract

“…La incidencia y prevalencia del dolor neuropático exacta se desconoce. Las estimaciones de prevalencia que se basan en causas específicas de dolor neuropático tienden a ser más bajas (2,1 %) que las fundamentadas en informes de los síntomas clásicos, proporcionando éstas valores de 6-8 %; en España se cifra en un 7,7 %, incluso más alta según distintos estudios (3). En cualquier caso, una mejor estimación de prevalencia poblacional del dolor con características neuropáticas es probable que se sitúe entre el 6,9 y el 10 % (4).…”

Section: Introductionunclassified

Lacosamida en el tratamiento del dolor neuropático

Montero¹,

Curado²

2016

Rev. Soc. Esp. Dolor.

View full text Add to dashboard Cite

Rev Soc Esp Dolor 2016; 23(6): 316-325Recibido: 30-11-15. Aceptado: 20-02-16. Dolor 2016;23(6):316-325. Alcántara Montero A y González Curado A. Lacosamida en el tratamiento del dolor neuropático. Rev Soc Esp ABSTRACTMost of the clinical practice guidelines consulted agree that tricyclics, dual (venlafaxine/duloxetine) antidepressants, gabapentin/pregabalin antiepileptics, lidocaine 5 % patches and capsaicin 8 % patches are the first-line drugs in the treatment of peripheral neuropathic pain, being tramadol and some strong opioids (morphine, oxycodone and tapentadol) second-line drugs treatment. Moreover, the prevalence of neuropathic pain refractory to treatment is about 1,5 % of the population, so that an estimated 50 % of patients not responding to prescribed treatment. There are other antiepileptics who not have neuropathic pain indication by regulatory agencies, such as lamotrigine, topiramate or oxcarbazepine, but are used in routine clinical practice off-label.Although not approved the use of lacosamide in the treatment of neuropathic pain, some authors believe that could be a good option for patients who do not respond to standard treatments.The following article summarizes the main pharmacological characteristics of lacosamide as well as the literature available in neuropathic pain.Key words: Lacosamide, neuropathic pain. RESUMENLa mayor parte de las guías de práctica clínica consultadas coinciden en señalar que los antidepresivos tricíclicos, duales (venlafaxina/duloxetina), los antiepilépticos gabapentina/pregabalina, apósitos de lidocaína 5 % y parches de capsaicina 8 % constituyen los fármacos de primera línea en el tratamiento del dolor neuropático periférico, siendo el tramadol y algunos opioides potentes (morfina, oxicodona y tapentadol) fármacos de segunda línea de tratamiento. Por otra parte, la prevalencia de dolor neuropático refractario al tratamiento se acerca al 1,5 % de la población, de forma que se calcula que un 50 % de los pacientes no responde al tratamiento prescrito. Existen otros antiepilépticos que no tienen indicación en dolor neuropático por las agencias reguladoras, como la lamotrigina, topiramato u oxcarbazepina, pero se utilizan en la práctica clínica habitual fuera de indicación.Aunque no está aprobado el uso de lacosamida en el tratamiento del dolor neuropático, algunos autores consideran que podría ser una buena opción para aquellos pacientes que no responden a los tratamientos habituales.En el siguiente artículo se resumen las principales características farmacológicas de lacosamida, así como la bibliografía disponible en dolor neuropático.Palabras clave: Lacosamida, dolor neuropático. INTRODUCCIÓNSe define el dolor neuropático (DN) como el dolor que aparece como consecuencia directa de una lesión o enfermedad del sistema somatosensorial (1). El DN crónico no tiene función biológica alguna, e impone con frecuencia alteraciones físicas, emocionales, sociales y económicas, las cuales dificultan profundamente la vida de los pacientes que lo sufren. Es un problema clínico imp...

show abstract

“…Most are national or regional studies [BASSOLS & AL., 1999;ELLIOTT & AL., 1999;KOLEVA & AL., 2005, LANTERI-MINET & AL., 2003, or compilations of national studies [GOUDAS & AL., 2005]. However, these studies only focused on specific pain disability (e.g.…”

Section: Introductionmentioning

confidence: 99%

Analysis of the medical and biological pain research literature in the European Union: A 2006 snapshot

et al. 2009

View full text Add to dashboard Cite

This study analyzed 2443 papers published in 2006 by European Union authors on pain-related research. Five EU countries (the UK, Germany, Italy, the Netherlands and France) each published > 200 papers while three countries (Cyprus, Malta and Estonia) published none; socio-economic indicators were related to each country's productivity. The 2443 papers were published in 592 journals and Cephalalgia, Pain and European Journal of Pain were the most prolific. Publications were also analyzed for intra-versus inter-EU/non-EU collaborations and subdisciplines profiles in Clinical Medicine and the Life Sciences for the World, USA, EU and the top-four EU countries were compared.

show abstract

Pain in primary care: an Italian survey

Cited by 56 publications

References 21 publications

Chronic Pain in German General Practice

Chronic Pain in German General Practice

Lacosamida en el tratamiento del dolor neuropático

Analysis of the medical and biological pain research literature in the European Union: A 2006 snapshot

Contact Info

Product

Resources

About